NanoTess chronic wound gel now in 14,000 Canadian pharmacies

NanoTess wound gel will now be available in over 14,000 pharmacies across Canada, a big increase in access for patients.
By Newsroom | Health, Canada |

NanoTess, a Calgary-based firm developing technology for chronic wound treatment, has secured a significant distribution deal with Embecta, a major player in diabetes care. This agreement will place NanoTess's topical gel, NanoSALV Catalytic, into over 14,000 pharmacies across Canada. The product, a gel featuring tiny catalytic particles, is designed to expedite the healing of persistent sores, including diabetic foot ulcers and venous leg ulcers.

This partnership signifies Embecta's entry into wound care product distribution within Canada, a move that expands its existing portfolio of diabetes-related devices like insulin delivery systems. The company highlights the arrangement as a means to broaden care options for the substantial population of Canadians managing diabetes, a condition often linked to difficult-to-heal wounds.

NanoSALV Catalytic utilizes what NanoTess terms a proprietary 'Catalytic Treatment Matrix' (CTM). This matrix reportedly facilitates the body's natural healing mechanisms and influences copper-dependent cellular signaling. According to Megan Leslie, CEO of NanoTess, the distribution agreement underscores a shared objective to enhance accessibility of wound care innovation for individuals in Canada living with diabetes.

Read More: Andhra Pradesh Drug-Free Campaign 'Dandi Yatra 2.0' Reaches 510 km

A Canadian Product with Growing Recognition

The NanoSALV Catalytic is described as a Canadian-made, award-winning medical device that has received authorization from Health Canada. Its application extends beyond general chronic wounds, with investigations into its efficacy for pressure injuries noted. While coverage can vary based on private insurance plans, the product is covered under Alberta's Drug Benefit List for certain applications, indicating a step towards broader public accessibility within that province. Reports suggest potential benefits such as reduced wound care costs and improved patient and staff well-being.

Early Observations and Clinical Interest

Clinical observations have pointed to the gel's effectiveness. In one instance, a healthcare professional noted a patient's wound, which had previously resisted healing, began to mend after a trial period with NanoSALV. This has apparently led to interest from international medical practitioners.

Read More: French Alan Insurtech gets new money, expands in Canada

Frequently Asked Questions

Q: Where can Canadians buy the NanoTess chronic wound gel starting now?
NanoTess chronic wound gel is now available in over 14,000 pharmacies across Canada. This is thanks to a new deal with Embecta, a company known for diabetes care products.
Q: What is NanoSALV Catalytic gel used for?
NanoSALV Catalytic gel is used to help heal slow-healing sores, like diabetic foot ulcers and venous leg ulcers. It uses tiny particles to help the body heal itself faster.
Q: Why is Embecta distributing NanoTess wound gel in Canada?
Embecta is distributing NanoTess wound gel to offer more care options for Canadians with diabetes, who often get hard-to-heal wounds. This also expands Embecta's product range in Canada.
Q: Is NanoSALV Catalytic gel approved and covered in Canada?
Yes, NanoSALV Catalytic is a Canadian-made product approved by Health Canada. It is covered under Alberta's Drug Benefit List for some uses, and may be covered by private insurance.
Q: What are the potential benefits of using NanoSALV Catalytic gel?
The gel may help wounds heal faster, potentially lowering costs for wound care. It could also improve the well-being of patients and healthcare staff.